'Intriguing' data On GSK's ICOS Agonist For Head And Neck Cancer

 
• By Kevin Grogan
  
Blacksmiths
In oncology, GSK is hoping to have more irons in the fire • Source: Shutterstock

More from Immuno-oncology

More from Anticancer